Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy | Zendy

Knorr David A. | Zendy; Ni Zhenya | Zendy; Hermanson David | Zendy; Hexum Melinda K. | Zendy; Bendzick Laura | Zendy; Cooper Laurence J.N. | Zendy; Lee Dean A. | Zendy; Kaufman Dan S. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinical‐Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

Author(s) -

Knorr David A.,

Ni Zhenya,

Hermanson David,

Hexum Melinda K.,

Bendzick Laura,

Cooper Laurence J.N.,

Lee Dean A.,

Kaufman Dan S.

Publication year - 2013

Publication title -

stem cells translational medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.781

H-Index - 71

eISSN - 2157-6580

pISSN - 2157-6564

DOI - 10.5966/sctm.2012-0084

Subject(s) - induced pluripotent stem cell , stem cell , cancer therapy , cancer stem cell , cancer , biology , human induced pluripotent stem cells , cell therapy , cancer research , embryonic stem cell , microbiology and biotechnology , genetics , gene

This study used a two‐stage culture system to efficiently produce natural killer (NK) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in the absence of cell sorting and without need for xenogeneic stromal cells. Although different hESC and iPSC lines had varying efficiencies in hematopoietic development, all cell lines tested could produce functional NK cells. This improved method to develop NK cells from human pluripotent stem cells provides a system for clinical‐scale expansion of antitumor lymphocytes and a genetically amenable platform to study human NK cell development.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research